Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.

January 17, 2025

Vol.51 No.02

Drugs & Targets

MAIA Biotechnology, BeiGene announce clinical supply agreement

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.

January 17, 2025

Vol.51 No.02

Conversation with The Cancer Letter

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

A low omega-6, omega-3 rich diet + fish oil may slow prostate cancer growth, UCLA phase III trial finds

A new phase III trial led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements, significantly reduced the growth rate of prostate cancer cells in men with early-stage disease.

January 10, 2025

Vol.51 No.01

Clinical Roundup

UCLA: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Physicians with the Lymphoma Research Foundation present research focused on immunotherapy, disparities at ASH 2024

Several physicians and lymphoma experts who work closely with the Lymphoma Research Foundation presented abstracts at the 66th annual ASH Annual Meeting and Exposition in San Diego, CA on Dec. 7-10, 2024.

January 10, 2025

Vol.51 No.01

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

YOU MAY BE INTERESTED IN

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

MAIA Biotechnology, BeiGene announce clinical supply agreement

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

A low omega-6, omega-3 rich diet + fish oil may slow prostate cancer growth, UCLA phase III trial finds

UCLA: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

Physicians with the Lymphoma Research Foundation present research focused on immunotherapy, disparities at ASH 2024

Renew today!

Subscriber content

Never miss an issue!

Login